Limited time offer! 10% off your first blood test order!
Nine-marker panel targeting post-menopausal bone and cardiovascular risk — lipids, inflammation, vitamin D, calcium, and PTH.
or 4 interest-free payments of £24.75 with Klarna
A targeted nine-marker panel for post-menopausal women assessing the key cardiovascular and bone-health risk factors that increase significantly after.
Oestrogen loss at menopause accelerates two major health risks: cardiovascular disease and osteoporosis. In the decade after menopause, women’s cardiovascular risk rises to match that of men the same age, while bone mineral density can decline by 2 to 3% per year in the early post-menopausal period.
The Menopause Bone and Heart Health Panel targets both risks with nine carefully selected markers. Cardiovascular: full lipid profile (total cholesterol, LDL, HDL, triglycerides, non-HDL) plus high-sensitivity CRP and homocysteine. Bone health: vitamin D (25-OH), corrected calcium, and parathyroid hormone (PTH) — the triad of markers most informative for assessing bone metabolism and fracture risk.
Vitamin D deficiency accelerates bone loss and is extremely common in post-menopausal women in the UK. Parathyroid hormone rises to compensate for low calcium availability, driving bone resorption. Corrected calcium identifies hypercalcaemia (as seen in primary hyperparathyroidism, which becomes more common after menopause).
Venous draw required. GMC-physician reviewed results within 3 to 5 working days.
Understand what each marker measures, why it matters, and what the science says — not just a list of numbers.
Full lipid profile; cardiovascular risk rises significantly in post-menopausal women due to loss of oestrogen's cardioprotective effects.
Vascular inflammation marker; chronic low-grade inflammation increases after menopause and predicts cardiovascular events.
B12 and folate-sensitive thrombotic risk marker; elevated levels increase stroke and cardiovascular disease risk.
Essential for calcium absorption and bone mineralisation; deficiency is extremely common in UK post-menopausal women.
Total calcium adjusted for albumin level; detects hypercalcaemia (seen in primary hyperparathyroidism and vitamin D toxicity).
Hormone that regulates calcium and phosphate; elevated PTH drives bone resorption and is common in vitamin D deficiency and primary hyperparathyroidism.
This panel is designed for adults who want a comprehensive, evidence-based picture of their metabolic health — not a GP referral panel.
Post-menopausal women concerned about osteoporosis and fracture risk
Those with cardiovascular risk factors wanting a comprehensive post-menopausal assessment
Women on HRT who want to monitor bone and cardiovascular health markers
Those with bone pain, fatigue, or muscle weakness wanting to exclude vitamin D and calcium disorders
This panel assesses key bone and cardiovascular risk markers but does not include sex hormones (oestradiol, testosterone), bone-specific resorption markers (CTX, P1NP), or a DEXA scan for bone density — all of which may be needed for comprehensive fracture risk assessment. Homocysteine is non-specific and can be elevated in B12/folate deficiency, kidney disease, or hypothyroidism, as well as genetic causes. PTH must be interpreted alongside calcium and vitamin D together; an isolated elevated PTH requires clinical context before drawing conclusions. Corrected calcium uses albumin to adjust total calcium; for most clinical purposes this is adequate, but ionised calcium may be preferred in certain clinical scenarios. Please discuss significantly elevated calcium or PTH with your GP promptly.
From order to physician-reviewed report in as little as three working days.
Three options designed to fit your schedule, location, and preference — all producing a laboratory-standard sample.
Adults 18+ in mainland UK. Not suitable if you have had a transfusion in the last 3 months.
Order anytime; kit dispatched within 24 hours Mon–Fri.
Allow 24–48 hours for sample transit on top of lab processing time.
Adults 18+ within 20 miles of a serviced city centre.
Mon–Sun, 06:00–20:00. Next-day booking typical.
Sample reaches the lab within 24 hours of collection.
Adults 16+ with photo ID. Paediatric draws by appointment at selected sites.
Mon–Fri, with Saturday hours at most metropolitan locations.
Samples processed same-day at the receiving clinic.
Every test is processed in a UKAS ISO 15189-accredited laboratory, overseen by GMC-registered physicians, and governed by UK GDPR. No overseas processing, no offshore data.
Follow these guidelines to ensure accurate, reproducible results. Most markers are sensitive to recent food, exercise, and sleep.
Can't find your answer? Our clinical support team is available Monday to Friday, 9am–5pm.
Contact supportOestrogen has significant cardioprotective effects throughout a woman’s reproductive years. It promotes HDL cholesterol (the protective form), reduces LDL and its oxidation, maintains arterial flexibility, reduces inflammatory markers, and has beneficial effects on the vascular endothelium. When oestrogen declines after menopause, these protections are lost. LDL tends to rise, HDL may fall, triglycerides often increase, and inflammatory markers including CRP may climb. Within 10 years of menopause, women’s cardiovascular risk approaches that of age-matched men — a major shift from their relative protection during the reproductive years.
Vitamin D is essential for the absorption of dietary calcium from the gut. Without adequate vitamin D, only a small fraction of ingested calcium is absorbed, leading to low circulating calcium. The parathyroid glands detect this low calcium and release more PTH, which instructs bone to release its calcium stores — effectively dissolving bone to maintain blood calcium levels. This process, when chronic, leads to bone mineral loss (osteomalacia in adults, rickets in children). Maintaining vitamin D levels above 75 nmol/L significantly improves calcium absorption and reduces the rate of post-menopausal bone loss.
Primary hyperparathyroidism is a condition in which one or more of the four parathyroid glands produce too much PTH — usually due to a benign adenoma. It is more common in post-menopausal women than in any other demographic, affecting around 1 in 500 to 1,000 adults in this group. The classic biochemical picture is elevated PTH with elevated calcium (in contrast to vitamin D deficiency, where PTH is elevated but calcium is normal or low). Many cases are asymptomatic but discovered incidentally; symptoms when present include kidney stones, bone pain, fatigue, and mood changes. This panel can identify this pattern.
HRT is the most effective treatment for menopausal symptoms and has well-established bone-protective effects — it reduces fracture risk significantly. For cardiovascular disease, the picture is more nuanced and depends on timing: HRT started within 10 years of menopause (the ‘timing hypothesis’) appears to have neutral or beneficial cardiovascular effects in most women; HRT started more than 10 to 20 years after menopause in older women may carry some increased cardiovascular risk. Current guidance from the British Menopause Society supports HRT as safe for most women under 60 or within 10 years of menopause, while acknowledging individual risk variation.
Annual monitoring of lipids, vitamin D, and calcium is a reasonable approach for most post-menopausal women. For women with confirmed vitamin D deficiency, retesting after 3 months of supplementation allows dose adjustment. For those with elevated PTH or calcium, more urgent follow-up with a GP is appropriate — your physician report will specify. Women on HRT should have a lipid panel annually to monitor the response to treatment. DEXA bone density scans (not included in this panel) are recommended by NICE for post-menopausal women with significant fracture risk factors and should be arranged through a GP.
Elevated PTH requires interpretation alongside calcium and vitamin D. If calcium is normal or low and vitamin D is deficient, the elevated PTH is likely a secondary response (secondary hyperparathyroidism) to the deficiency — correcting vitamin D should normalise PTH. If calcium is elevated alongside PTH, primary hyperparathyroidism should be excluded, and a GP referral for further evaluation (repeat testing, imaging of parathyroid glands) is recommended. Your Trupoint Health physician report will categorise your pattern and advise on urgency. Elevated calcium with elevated PTH should always prompt medical review.
